BDTX
Income statement / Annual
Last year (2023), Black Diamond Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Black Diamond Therapeutics, Inc.'s net income was -$82.44 M.
See Black Diamond Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$437,000.00 |
$3.24 M |
$2.22 M |
$600,000.00 |
$47,000.00 |
$44,000.00 |
$24,000.00 |
| Gross Profit |
-$437,000.00 |
-$3.24 M |
-$2.22 M |
-$600,000.00 |
-$47,000.00 |
-$44,000.00 |
-$24,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$59.35 M
|
$64.44 M
|
$96.83 M
|
$48.21 M
|
$21.75 M
|
$6.95 M
|
$3.45 M
|
| General & Administrative
Expenses |
$27.11 M
|
$28.39 M
|
$30.04 M
|
$21.36 M
|
$7.58 M
|
$1.95 M
|
$666,000.00
|
| Selling & Marketing
Expenses |
$27.08 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$27.11 M
|
$28.39 M
|
$30.04 M
|
$21.36 M
|
$7.58 M
|
$1.95 M
|
$666,000.00
|
| Other Expenses |
$0.00 |
-$354,000.00 |
-$2.19 M |
-$1.72 M |
$6,000.00 |
-$16,000.00 |
-$6,000.00 |
| Operating Expenses |
$86.46 M |
$92.83 M |
$126.87 M |
$69.57 M |
$29.33 M |
$8.90 M |
$4.12 M |
| Cost And Expenses |
$86.46 M |
$92.83 M |
$126.87 M |
$69.57 M |
$29.33 M |
$8.90 M |
$4.12 M |
| Interest Income |
$1.92 M |
$2.03 M |
$3.46 M |
$4.04 M |
$461,000.00 |
$4,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$3.91 M |
$0.00 |
$1,000.00 |
$0.00 |
$0.00 |
$65,000.00 |
| Depreciation &
Amortization |
$437,000.00
|
$3.24 M
|
$2.22 M
|
$600,000.00
|
$47,000.00
|
$44,000.00
|
$24,000.00
|
| EBITDA |
-$86.02 M
|
-$95.06 M
|
-$125.60 M
|
-$67.25 M
|
-$22.94 M
|
-$8.87 M
|
-$4.10 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$4.02 M
|
$3.91 M
|
$1.28 M
|
$2.32 M
|
-$26.35 M
|
-$31,000.00
|
-$418,000.00
|
| Income Before Tax |
-$82.44 M |
-$88.92 M |
-$125.60 M |
-$67.25 M |
-$35.26 M |
-$8.93 M |
-$4.60 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$4.40 M |
-$2.39 M |
-$1.78 M |
$5.89 M |
-$27,000.00 |
$59,000.00 |
| Net Income |
-$82.44 M |
-$84.52 M |
-$123.20 M |
-$65.48 M |
-$41.14 M |
-$8.93 M |
-$4.60 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.88 |
-2.33 |
-3.4 |
-1.99 |
-1.15 |
-0.64 |
-0.64 |
| EPS Diluted |
-1.88 |
-2.33 |
-3.4 |
-1.99 |
-1.15 |
-0.64 |
-0.64 |
| Weighted Average Shares
Out |
$43.95 M
|
$36.33 M
|
$36.19 M
|
$32.91 M
|
$35.91 M
|
$13.95 M
|
$7.20 M
|
| Weighted Average Shares
Out Diluted |
$43.95 M
|
$36.33 M
|
$36.19 M
|
$32.91 M
|
$35.91 M
|
$13.95 M
|
$7.20 M
|
| Link |
|
|
|
|
|
|
|
